Quick Facts
  • wavy circle icon with check mark inside
    Expertise:
    Video-Assisted Surgery
    Immunotherapy
  • magnifying glass with heart icon
    Speciality:
    Thoracic Surgery
  • gender symbols interlocked icon
    Gender:
    Male
  • chat box with different language translations icon
    Language:
    English
  • pin location icon
    Primary Location:
    UCLA Health

Get to Know Dr. Bryan Burt

Dr. Bryan Burt received his medical degree from Weill Medical College of Cornell University in New York. While training under mesothelioma pioneer Dr. David Sugarbaker, he completed residencies in general surgery and thoracic surgery at Brigham and Women’s Hospital in Boston.

As professor and chief of the division of thoracic surgery at UCLA, Burt focuses on developing innovative mesothelioma surgical treatments that result in a shorter recovery time. He is board certified by the American Board of Surgery and the American Board of Thoracic Surgery.

Burt offers two primary surgeries for pleural mesothelioma: extrapleural pneumonectomy and pleurectomy and decortication. EPP, a technique Sugarbaker developed, is an aggressive mesothelioma surgery that removes an entire lung and several other chest structures affected by cancer.

The pleurectomy and decortication procedure allows patients to keep their lungs intact. This surgery involves removing the lungs’ protective lining and any chest structures where cancer has spread. The surgeon then extracts any visible tumor mass from the chest.

Burt uses the latest surgical technology and is a skilled robotic surgeon. He also leads a research laboratory funded by the National Institutes of Health and has completed several investigator-initiated clinical trials of novel immunotherapeutic strategies for patients with thoracic malignancies.

Mesothelioma specialist speaking with a patient and his wife
Get the Best Treatment
Get help connecting with Dr. Burt and find the treatment that’s best for you or your loved one.
Get Help Now

Specialties of Dr. Bryan Burt

  • Lung cancer
  • Pleural mesothelioma
  • Esophageal cancer
  • Video-assisted thoracoscopic surgery
  • Immunotherapy
  • Research
Contact Dr. Bryan Burt

Dr. Bryan Burt’s Experience and Medical Education

  • UCLA Health
  • Baylor College of Medicine
  • Brigham and Women’s Hospital/Harvard Medical School (Residency and fellowship)
  • Weill Medical College of Cornell University (M.D.)
  • American College of Surgeons (Fellow)

Awards and Certifications

  • Board certified in thoracic and general surgery
  • Feature editor, The Journal of Cardiovascular and Thoracic Surgery
  • Norton Rose Fulbright Faculty Excellence Award for Enduring Education, Baylor College of Medicine
  • Early Career Faculty Award for Excellence in Patient Care, Baylor College of Medicine
  • Peter Bent Brigham Scholar Award, Brigham and Women’s Hospital
  • Clarence Coryell Prize in Surgery, Weill Medical College
  • William C. Thro Memorial Prize in Pathophysiology, Weill Medical College
  • Dr. Harold Lamport Biomedical Research Prize, Weill Medical College

Mesothelioma Clinical Trials Under Bryan M. Baylor, M.D.

  • MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma.
  • MTG201 Plus Nivolumab in Patients With Relapsed Pleural Mesothelioma
  • Study of Cytoreductive Surgery and Hyperthermic Intraoperative Chemotherapy With Pemetrexed and Cisplatin for Malignant Pleural Mesotheliomas

Publications of Dr. Bryan M. Burt

  • Burt, B.M. (2020, November 1). Malignant Pleural Mesothelioma. Thoracic Surgery Clinics.
  • Olive, J.K. & Burt, B.M. (2020, September 15). Commentary: Preventative indications for major resection. JTCVS Techniques.
  • Burt, B.M. et al. (2020, June). Preoperative prediction of unresectability in malignant pleural mesothelioma. The Journal of Thoracic and Cardiovascular Surgery.
  • Groth, S.S. & Burt, B.M. (2019, December). Percentage of tumor-infiltrating lymphocytes after chemoradiation therapy for locally advanced esophageal squamous cell carcinoma: a biomarker for pathological response rates and cancer-specific survival? Annals of Translational Medicine.